Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
Wilfried Dinh, Senior Clinical Program Leader at Boehringer Ingelheim, shared a post on LinkedIn:
“Antiplatelet therapy in 2026: duration is becoming a dynamic decision
Key takeaway: contemporary antiplatelet therapy is moving from fixed regimens toward individualized intensity, duration and de-escalation based on evolving thrombotic and bleeding risk.
- Elective PCI for CCD: typically 6 months DAPT.
- ACS without high bleeding risk: more or equal to 12 months remains the default.
- Selected patients may transition after 1–3 months to P2Y12 monotherapy.
- With long-term anticoagulation, triple therapy should generally be minimized.
Comment: shorter DAPT is not inherently better.
Many trials enrolled selected, relatively lower-thrombotic-risk populations.
The more important concept is serial reassessment, because bleeding and ischemic risk evolve differently over time.
Disclaimer: Views are solely my own as a private individual, physician, and researcher.
They do not represent my employer, colleagues, or affiliated organizations. For scientific education and professional discussion only, not medical advice.”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period
-
Oct 17, 2026, 16:24W. Alberto Sifuentes Giraldo: Exploring Peripheral Macrovascular Thrombosis in CAPS
-
Oct 17, 2026, 16:17Rishabh Jain: Could Rusfertide Transform Polycythemia Vera Management?
-
Oct 17, 2026, 16:16Fabrice Cognasse: Advancing Transfusion Medicine Through International Collaboration
-
Oct 17, 2026, 16:10Abdul Muqtadir Abbasi: PNH – How to Interpret Flow Cytometry
-
Oct 17, 2026, 16:10Lakshmi Kattamuri: Contemporary Evidence on Antithrombotic Therapy in AF and Chronic Coronary Disease
-
Oct 17, 2026, 16:05Gregg W. Stone: Short-Term DOACs Show Advantage Over DAPT Post-LAAO